Update on Tissue Factor Detection in Blood in 2024: A Narrative Review

Abstract

Tissue factor (TF) is a transmembrane protein essential for hemostasis. Different forms of active TF circulate in the blood, either as a component of blood cells and extracellular vesicles (EVs) or as a soluble plasma protein. Accumulating experimental and clinical evidence suggests that TF plays an important role in thrombosis. Many in-house and commercially available assays have been developed to measure TF-dependent procoagulant activity or antigen in blood and have shown promising results for the prediction of disease outcomes or the occurrence of thrombosis events in diseases such as cancer or infectious coagulopathies. This review addresses the different assays that have been published for measuring circulating TF antigen and/or activity in whole blood, cell-free plasma, and EVs and discusses the main preanalytical and analytical parameters that impact results and their interpretation, highlighting their strengths and limitations. In the recent decade, EVTF assays have been significantly developed. Among them, functional assays that use a blocking anti-TF antibody or immunocapture to measure EVTF activity have higher specificity and sensitivity than antigen assays. However, there is still a high variability between assays. Standardization and automatization are prerequisites for the measurement of EVTF in clinical laboratories.

Keywords

tissue factor - extracellular vesicles - functional assays - antigenic assays - flow cytometry

Publication History

Received: 01 June 2024

Accepted: 06 August 2024

Article published online:
23 October 2024

• References

• 1 Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost 2019; 45 (04) 385-395
• 2 Belting M, Dorrell MI, Sandgren S. et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10 (05) 502-509
• 3 Lacroix R, Vallier L, Bonifay A. et al. Microvesicles and cancer associated thrombosis. Semin Thromb Hemost 2019; 45 (06) 593-603
• 4 Khorana AA, Francis CW, Menzies KE. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6 (11) 1983-1985
• 5 Guervilly C, Bonifay A, Burtey S. et al. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Adv 2021; 5 (03) 628-634
• 6 Trepesch C, Nitzsche R, Glass A, Kreikemeyer B, Schubert JK, Oehmcke-Hecht S. High intravascular tissue factor-but not extracellular microvesicles-in septic patients is associated with a high SAPS II score. J Intensive Care 2016; 4 (01) 34
• 7 Kasthuri RS, Glover SL, Jonas W. et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood 2012; 119 (22) 5285-5293
• 8 Chantrathammachart P, Mackman N, Sparkenbaugh E. et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood 2012; 120 (03) 636-646
• 9 Shet AS, Aras O, Gupta K. et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102 (07) 2678-2683
• 10 Key NS, Slungaard A, Dandelet L. et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91 (11) 4216-4223
• 11 Suefuji H, Ogawa H, Yasue H. et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134 (2, Pt 1): 253-259
• 12 Lok CAR, Jebbink J, Nieuwland R. et al. Leukocyte activation and circulating leukocyte-derived microparticles in preeclampsia. Am J Reprod Immunol 2009; 61 (05) 346-359
• 13 Tesselaar MET, Romijn FPHTM, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5 (03) 520-527
• 14 Tesselaar MET, Romijn FPHTM, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 7 (08) 1421-1423
• 15 Thaler J, Ay C, Mackman N. et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10 (07) 1363-1370
• 16 Bharthuar A, Khorana AA, Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013; 132 (02) 180-184
• 17 Hernández C, Orbe J, Roncal C. et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost 2013; 110 (03) 598-608
• 18 Woei-A-Jin FJSH, Tesselaar MET, Garcia Rodriguez P, Romijn FPHTM, Bertina RM, Osanto S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?. Br J Cancer 2016; 115 (03) 332-338
• 19 Hisada Y, Thålin C, Lundström S, Wallén H, Mackman N. Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients. Thromb Res 2018; 165: 1-5
• 20 Hisada Y, Sachetto ATA, Mackman N. Circulating tissue factor-positive extracellular vesicles and their association with thrombosis in different diseases. Immunol Rev 2022; 312 (01) 61-75
• 21 Hell L, Däullary T, Burghart V. et al. Extracellular vesicle-associated tissue factor activity in prostate cancer patients with disseminated intravascular coagulation. Cancers (Basel) 2021; 13 (07) 1487
• 22 Thaler J, Pabinger I, Sperr WR, Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res 2014; 133 (03) 303-305
• 23 Langer F, Spath B, Haubold K. et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 2008; 87 (06) 451-457
• 24 Kasthuri RS, Hisada Y, Ilich A, Key NS, Mackman N. Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer. Res Pract Thromb Haemost 2020; 4 (04) 636-643
• 25 Faille D, Bourrienne MC, de Raucourt E. et al. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget 2018; 9 (41) 26453-26465
• 26 van Es N, Hisada Y, Di Nisio M. et al. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res 2018; 166: 54-59
• 27 van Doormaal F, Kleinjan A, Berckmans RJ. et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012; 108 (01) 160-165
• 28 Campbell RA, Hisada Y, Denorme F. et al. Comparison of the coagulopathies associated with COVID-19 and sepsis. Res Pract Thromb Haemost 2021; 5 (04) e12525
• 29 Butenas S. Tissue factor structure and function. Scientifica (Cairo) 2012; 2012: 964862
• 30 Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost 2013; 11 (Suppl. 01) 277-284
• 31 Chen F, Zhao Z, Zhou J, Lu Y, Essex DW, Wu Y. Protein disulfide isomerase enhances tissue factor-dependent thrombin generation. Biochem Biophys Res Commun 2018; 501 (01) 172-177
• 32 Tait JF, Gibson D. Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content. Arch Biochem Biophys 1992; 298 (01) 187-191
• 33 Nemerson Y. The phospholipid requirement of tissue factor in blood coagulation. J Clin Invest 1968; 47 (01) 72-80
• 34 Astrup T. Assay and content of tissue thromboplastin in different organs. Thromb Diath Haemorrh 1965; 14 (3-4): 401-416
• 35 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134 (05) 1087-1097
• 36 Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone Jr MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986; 83 (12) 4533-4537
• 37 Sachetto ATA, Mackman N. Monocyte tissue factor expression: LPS induction and roles in pathological activation of coagulation. Thromb Haemost 2023; 123 (11) 1017-1033
• 38 Maugeri N, Manfredi AA. Tissue factor expressed by neutrophils: another piece in the vascular inflammation puzzle. Semin Thromb Hemost 2015; 41 (07) 728-736
• 39 Nakamura S, Imamura T, Okamoto K. Tissue factor in neutrophils: yes. J Thromb Haemost 2004; 2 (02) 214-217
• 40 Osterud B, Rao LV, Olsen JO. Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytes. Thromb Haemost 2000; 83 (06) 861-867
• 41 Østerud B. Tissue factor in neutrophils: no. J Thromb Haemost 2004; 2 (02) 218-220
• 42 Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets. Blood 2010; 116 (05) 854-855
• 43 Panes O, Matus V, Sáez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood 2007; 109 (12) 5242-5250
• 44 Siddiqui FA, Desai H, Amirkhosravi A, Amaya M, Francis JL. The presence and release of tissue factor from human platelets. Platelets 2002; 13 (04) 247-253
• 45 Egorina EM, Sovershaev MA, Olsen JO, Østerud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood 2008; 111 (03) 1208-1216
• 46 Giesen PL, Rauch U, Bohrmann B. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96 (05) 2311-2315
• 47 Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266 (04) 2158-2166
• 48 Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96 (12) 1233-1239
• 49 Shustova ON, Antonova OA, Golubeva NV. et al. Differential procoagulant activity of microparticles derived from monocytes, granulocytes, platelets and endothelial cells: impact of active tissue factor. Blood Coagul Fibrinolysis 2017; 28 (05) 373-382
• 50 Aharon A, Tamari T, Brenner B. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 2008; 100 (05) 878-885
• 51 Holnthoner W, Bonstingl C, Hromada C. et al. Endothelial cell-derived extracellular vesicles size-dependently exert procoagulant activity detected by thromboelastometry. Sci Rep 2017; 7 (01) 3707
• 52 Hisada Y, Mackman N. Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival. Curr Opin Hematol 2019; 26 (05) 349-356
• 53 Li M, Yu D, Williams KJ, Liu ML. Tobacco smoke induces the generation of procoagulant microvesicles from human monocytes/macrophages. Arterioscler Thromb Vasc Biol 2010; 30 (09) 1818-1824
• 54 Scalise V, Lombardi S, Sanguinetti C. et al. A novel prothrombotic role of proprotein convertase subtilisin kexin 9: the generation of procoagulant extracellular vesicles by human mononuclear cells. Mol Biol Rep 2022; 49 (05) 4129-4134
• 55 Featherby S, Madkhali Y, Maraveyas A, Ettelaie C. Apixaban suppresses the release of TF-positive microvesicles and restrains cancer cell proliferation through directly inhibiting TF-fVIIa activity. Thromb Haemost 2019; 119 (09) 1419-1432
• 56 Jin M, Drwal G, Bourgeois T, Saltz J, Wu HM. Distinct proteome features of plasma microparticles. Proteomics 2005; 5 (07) 1940-1952
• 57 Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005; 105 (07) 2764-2770
• 58 Berckmans RJ, Nieuwland R, Böing AN, Romijn FPHTM, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85 (04) 639-646
• 59 Nielsen VG, Audu P, Cankovic L. et al. Qualitative thrombelastographic detection of tissue factor in human plasma. Anesth Analg 2007; 104 (01) 59-64
• 60 Ollivier V, Wang J, Manly D. et al. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res 2010; 125 (01) 90-96
• 61 Zillmann A, Luther T, Müller I. et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001; 281 (02) 603-609
• 62 Santucci RA, Erlich J, Labriola J. et al. Measurement of tissue factor activity in whole blood. Thromb Haemost 2000; 83 (03) 445-454
• 63 Tanratana P, Sachetto ATA, Mast AE, Mackman N. An anti-tissue factor pathway inhibitor antibody increases tissue factor activity in extracellular vesicles isolated from human plasma. Res Pract Thromb Haemost 2023; 8 (01) 102275
• 64 Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 1999; 60 (03) 175-180
• 65 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
• 66 Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J Thromb Haemost 2006; 4 (08) 1747-1755
• 67 Bis J, Vojáček J, Dusek J. et al. Time-course of tissue factor plasma level in patients with acute coronary syndrome. Physiol Res 2009; 58 (05) 661-667
• 68 Steppich BA, Braun SL, Stein A. et al. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb J 2009; 7: 11
• 69 Franco C, Lacroix R, Vallier L. et al. A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids. Thromb Res 2020; 196: 414-424
• 70 Kristensen SR, Nybo J. A sensitive tissue factor activity assay determined by an optimized thrombin generation method. PLoS One 2023; 18 (07) e0288918
• 71 Østerud B, Latysheva N, Schoergenhofer C, Jilma B, Hansen JB, Snir O. A rapid, sensitive, and specific assay to measure TF activity based on chromogenic determination of thrombin generation. J Thromb Haemost 2022; 20 (04) 866-876
• 72 Vallier L, Bouriche T, Bonifay A. et al. Increasing the sensitivity of the human microvesicle tissue factor activity assay. Thromb Res 2019; 182: 64-74
• 73 Lee RD, Barcel DA, Williams JC. et al. Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 2012; 129 (01) 80-85
• 74 Sachetto ATA, Archibald SJ, Hisada Y. et al. Tissue factor activity of small and large extracellular vesicles in different diseases. Res Pract Thromb Haemost 2023; 7 (03) 100124
• 75 Chiva-Blanch G, Laake K, Myhre P. et al. Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity. PLoS One 2017; 12 (02) e0172558
• 76 Balbi C, Burrello J, Bolis S. et al. Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS-CoV-2 infection. EBioMedicine 2021; 67: 103369
• 77 Weiss R, Mostageer M, Eichhorn T. et al. The fluorochrome-to-protein ratio is crucial for the flow cytometric detection of tissue factor on extracellular vesicles. Sci Rep 2024; 14 (01) 6419
• 78 Price JMJ, Hisada Y, Hazeldine J. et al. Detection of tissue factor-positive extracellular vesicles using the ExoView R100 system. Res Pract Thromb Haemost 2023; 7 (04) 100177
• 79 Hisada Y, Auriemma AC, Alexander W, Ay C, Mackman N. Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy. Thromb Res 2017; 150: 65-72
• 80 Sachetto ATA, Archibald SJ, Bhatia R, Monroe D, Hisada Y, Mackman N. Evaluation of four commercial ELISAs to measure tissue factor in human plasma. Res Pract Thromb Haemost 2023; 7 (03) 100133
• 81 Claussen C, Rausch AV, Lezius S. et al. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. Thromb Res 2016; 141: 39-48
• 82 Archibald SJ, Hisada Y, Bae-Jump VL, Mackman N. Evaluation of a new bead-based assay to measure levels of human tissue factor antigen in extracellular vesicles in plasma. Res Pract Thromb Haemost 2022; 6 (02) e12677
• 83 Hellum M, Øvstebø R, Trøseid AMS, Berg JP, Brandtzaeg P, Henriksson CE. Microparticle-associated tissue factor activity measured with the Zymuphen MP-TF kit and the calibrated automated thrombogram assay. Blood Coagul Fibrinolysis 2012; 23 (06) 520-526
• 84 Tatsumi K, Antoniak S, Monroe III DM, Khorana AA, Mackman N. Subcommittee on Hemostasis and Malignancy of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1932-1934
• 85 Tanratana P, Azevedo Sachetto AT, Mackman N. “A rapid, sensitive, and specific assay to measure tissue factor activity based on chromogenic determination of thrombin generation”: comment from Tanratana et al. J Thromb Haemost 2023; 21 (04) 1059-1061
• 86 Bonifay A, Mackman N, Hisada Y. et al. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology. J Thromb Haemost 2024;S1538-7836(24)00367-2
• 87 Hu Y, Hell L, Kendlbacher RA. et al. Human milk triggers coagulation via tissue factor-exposing extracellular vesicles. Blood Adv 2020; 4 (24) 6274-6282
• 88 Nieuwland R, Gardiner C, Dignat-George F. et al. Toward standardization of assays measuring extracellular vesicle-associated tissue factor activity. J Thromb Haemost 2019; 17 (08) 1261-1264
• 89 Gheldof D, Haguet H, Dogné JM. et al. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. J Thromb Thrombolysis 2017; 43 (02) 224-232
• 90 Rosell A, Havervall S, von Meijenfeldt F. et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality. Arterioscler Thromb Vasc Biol 2020;
• 91 Koyama T, Nishida K, Ohdama S. et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87 (02) 343-347
• 92 Hisada Y, Mackman N. Measurement of tissue factor activity in extracellular vesicles from human plasma samples. Res Pract Thromb Haemost 2018; 3 (01) 44-48
• 93 Beckmann L, Mäder J, Voigtlaender M. et al. Inhibition of protein disulfide isomerase with PACMA-31 regulates monocyte tissue factor through transcriptional and posttranscriptional mechanisms. Thromb Res 2022; 220: 48-59
• 94 Aswad MH, Kissova J, Ovesna P, Rihova L, Penka M. The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms. In Vivo 2021; 35 (06) 3345-3353
• 95 Ettelaie C, Su S, Li C, Collier MEW. Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells. Microvasc Res 2008; 76 (03) 152-160
• 96 Berckmans RJ, Sturk A, van Tienen LM, Schaap MCL, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood 2011; 117 (11) 3172-3180
• 97 Chiva-Blanch G, Laake K, Myhre P. et al. High adherence to the Nordic diet is associated with lower levels of total and platelet-derived circulating microvesicles in a Norwegian population. Nutrients 2019; 11 (05) 1114
• 98 Campello E, Spiezia L, Radu CM. et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011; 127 (05) 473-477